# US 2025/0082718 A1 · Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082718 A1
- Document ID: US20250082718A1
- Status: Published application
- Kind: A1
- Application number: 18/956,119
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2005-12-22
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Holger Petersen; Markus Ahlheim
- Web page: https://patentgrep.com/patent/US20250082718A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5089: {Processes}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/31: Somatostatins
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAS).

## Claims

### Claim 1

A sustained release pharmaceutical composition in form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different polylactide-co-glycolide polymers (PLGAs), wherein the PLGAs are present as polymer blend, and wherein the microparticles are of a single composition and wherein the lactide: glycolide ratios of the different PLGAs are different from each other.

### Claim 2

A sustained release pharmaceutical composition in form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different polylactide-co-glycolide polymers (PLGAs), wherein the lactide: glycolide ratios of the different PLGAs are different from each other, wherein the sustained release pharmaceutical composition is a mixture of depots, which is a mixture of two microparticles of different compositions, each with one different PLGA.

### Claim 3 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the PLGAs have a lactide: glycolide monomer ratio of 100:0 to 40:60.

### Claim 4 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the PLGAs have a lactide: glycolide monomer ratio of 90:10 to 40:60.

### Claim 5 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the PLGAs have a lactide: glycolide monomer ratio of 85:15 to 65:35.

### Claim 6 (depends on 1)

The sustained release pharmaceutical composition according to claims 1, wherein the inherent viscosity of the PLGAs is below 0.9 dl/g in chloroform.

### Claim 7 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the inherent viscosity of the PLGAs is below 0.8 dl/g in chloroform.

### Claim 8 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein at least two PLGAs are linear.

### Claim 9 (depends on 1)

The sustained release pharmaceutical composition according to claim 1 comprising the pamoate salt of octreotide.

### Claim 10 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the release of the active ingredient is three or more months.

### Claim 11 (depends on 1)

The sustained release pharmaceutical composition according to claim 1, wherein the microparticles are additionally mixed, covered or coated with an anti-agglomerating agent.

### Claim 12 (depends on 11)

The sustained release pharmaceutical composition according to claim 11, wherein the microparticles are coated with an anti-agglomerating agent and the anti-agglomerating agent is present in an amount of less than 2% by weight of the microparticles.

### Claim 13 (depends on 11)

The sustained release pharmaceutical composition according to claim 11, wherein the anti-agglomerating agent is mannitol.

### Claim 14 (depends on 1)

The sustained release pharmaceutical composition according to claim 1 sterilized by gamma irradiation.

### Claim 15 (depends on 1)

A process of manufacturing microparticles according to claim 1 comprising
(i) preparation of an internal organic phase comprising
(ia) dissolving the two or more different PLGA polymers in a suitable organic solvent or solvent mixture;
(ib) dissolving/suspending/emulsification of octreotide or a pharmaceutically-acceptable salt thereof in the polymer solution obtained in step (ia);
(ii) preparation of an external aqueous phase containing stabilizers;
(iii) mixing the internal organic phase with the external aqueous phase to form an emulsion; and
(iv) hardening the microparticles by solvent evaporation or solvent extraction, washing the microparticles, drying the microparticles and sieving the microparticles.

### Claim 16 (depends on 2)

A process of manufacturing the sustained release pharmaceutical composition according to claim 2, wherein the polylactide-co-glycolide polymers (PLGAs) are present in a mixture of depots, comprising
(i) preparation of an internal organic phase comprising
(ia) dissolving one PLGA polymer in an organic solvent or solvent mixture;
(ib) dissolving/suspending/emulsification of octreotide or an aqueous solution of octreotide in the polymer solution obtained in step (ia);
(ii) preparation of an external aqueous phase containing stabilizers;
(iii) mixing the internal organic phase with the external aqueous phase to form an emulsion;
(iv) hardening the microparticles by solvent evaporation or solvent extraction, washing the microparticles, drying the microparticles; and
(v) mixing the obtained microparticles with the other microparticles obtained from the same process except the PLGA polymer used in that process is different, and wherein the lactide: glycolide ratios of the different PLGAs are different from each other.

### Claim 17 (depends on 15)

Microparticles obtained by the process according to claim 15.

### Claim 18 (depends on 17)

A sustained release pharmaceutical composition comprising microparticles according to claim 17.

### Claim 19 (depends on 1)

An administration kit comprising the pharmaceutical composition according to claim 1 in a vial, together with a water-based vehicle in an ampoule, vial or prefilled syringe or as microparticles and vehicle separated in a double chamber syringe.
